Breaking News Instant updates and real-time market news.

CRSP

Crispr Therapeutics

$106.67 /

-1.1 (-1.02%)

07:14
10/21/20
10/21
07:14
10/21/20
07:14

Crispr Therapeutics reports top-line results from Phase 1 CARBON trial of CTX110

CRISPR Therapeutics announced top-line results from the Company's ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies. The Phase 1 CARBON trial is an open-label, multicenter study evaluating the safety and efficacy of CTX110 in adult patients with relapsed or refractory non-Hodgkin lymphoma, who have received at least two prior lines of therapy. As of the September 28, 2020, data cutoff, 12 patients were enrolled and infused with CTX110. Data are reported for the 11 patients who had at least completed their one-month assessment as of the data cutoff date. Patients were infused with CTX110 following three days of lymphodepletion using fludarabine and cyclophosphamide. The primary endpoints include safety as measured by the incidence of dose limiting toxicities and overall response rate. Key secondary endpoints include duration of response, progression-free survival and overall survival. No DLTs were observed. There were no cases of Graft-vs-Host Disease despite high HLA-mismatch between allogeneic CAR-T donors and patients. No infusion reactions to either lymphodepleting chemotherapy or CTX110 were observed. Cytokine Release Syndrome occurred in three patients and in each case was Grade 2 or below and resolved with tocilizumab administration. One patient had Grade 2 Immune Effector Cell-Associated Neurotoxicity Syndrome that improved within 24 hours with standard interventions. Two additional serious adverse events occurred after CTX110 infusion, both of which resolved and were determined to be unrelated to disease progression or CTX110. One patient received Dose Level 4 of CTX110. On Day 5, the patient experienced Grade 2 CRS which resolved in 5 days. The PET/CT assessment at Day 25 showed the patient had achieved a complete response. The following day, the patient was hospitalized with febrile neutropenia and developed symptoms of short-term memory loss and confusion. The symptoms eventually progressed to significant obtundation that required intubation. He was initially treated for ICANS with steroids, anakinra and intrathecal chemotherapy without improvement. The patient was later found to have reactivation of HHV-6 and HHV-6 encephalitis and treated with antiviral therapy. The decision was made to withdraw supportive care and the patient died 52 days after CTX110 infusion. Early evidence of dose-dependent anti-tumor activity was seen with CTX110. Disease assessment was performed by centralized independent radiological review according to the 2014 Lugano response criteria. Complete response was achieved at Dose Levels 2, 3, and 4. At DL3, two out of four patients had a complete response. These two patients remain in CR. The four patients with CR had deep responses including the complete resolution of extranodal disease, normalization of all nodal disease to 1.5 cm or smaller, and a Deauville score of 2 or lower. Additionally, one of these patients who had 30% lymphoblasts in the bone marrow achieved complete clearance after CTX110 infusion. CR was achieved both in patients with diffuse large B-cell lymphoma and with transformed follicular lymphoma, as well as in patients who were primary refractory and who had relapsed after autologous stem cell transplant. At DL2 and above, CTX110 was detected at multiple time points in all patients, with peak expansion occurring at 1-2 weeks and cells detected as late as 180 days post-infusion.

  • 21

    Nov

  • 01

    Jul

CRSP Crispr Therapeutics
$106.67 /

-1.1 (-1.02%)

10/05/20
Fly Intel: Top five analyst initiations
10/05/20 BofA
Crispr Therapeutics initiated with a Buy at BofA
10/05/20 BofA
Crispr Therapeutics initiated with a Buy at BofA
09/22/20 Piper Sandler
Crispr Therapeutics remains a top pick at Piper Sandler

TODAY'S FREE FLY STORIES

Earnings
American Woodmark reports Q2 adjusted EPS $1.97, consensus $1.88 » 06:31
11/24/20
11/24
06:31
11/24/20
06:31
AMWD

American Woodmark

$104.75 /

+6.28 (+6.38%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMWD American Woodmark
$104.75 /

+6.28 (+6.38%)

AMWD American Woodmark
$104.75 /

+6.28 (+6.38%)

11/23/20 Baird
American Woodmark designated a Fresh Pick at Baird
09/22/20 Zelman
American Woodmark upgraded to Buy from Hold at Zelman
08/04/20 Loop Capital
American Woodmark price target raised to $97 from $79 at Loop Capital
07/08/20 Wells Fargo
American Woodmark price target raised to $78 from $62 at Wells Fargo
AMWD American Woodmark
$104.75 /

+6.28 (+6.38%)

AMWD American Woodmark
$104.75 /

+6.28 (+6.38%)

Earnings
Tiffany reports Q3 EPS 98c, consensus 66c » 06:31
11/24/20
11/24
06:31
11/24/20
06:31
TIF

Tiffany

$131.50 /

+0.07 (+0.05%)

Reports Q3 revenue $1B,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TIF Tiffany
$131.50 /

+0.07 (+0.05%)

TIF Tiffany
$131.50 /

+0.07 (+0.05%)

10/28/20
LVMH, Tiffany near agreement on $131.50 per share price, WSJ reports
10/16/20 William Blair
Tiffany results strengthen legal standing against LVMH, says William Blair
09/10/20 Wells Fargo
Tiffany price target lowered to $120 from $135 at Wells Fargo
08/25/20 Oppenheimer
Opco 'turning more concerned' LVMH could reduce Tiffany buyout price
TIF Tiffany
$131.50 /

+0.07 (+0.05%)

TIF Tiffany
$131.50 /

+0.07 (+0.05%)

TIF Tiffany
$131.50 /

+0.07 (+0.05%)

TIF Tiffany
$131.50 /

+0.07 (+0.05%)

Recommendations
Houghton Mifflin price target raised to $3 from $2.50 at Citi » 06:31
11/24/20
11/24
06:31
11/24/20
06:31
HMHC

Houghton Mifflin

$2.79 /

+0.055 (+2.01%)

Citi analyst Jason…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HMHC Houghton Mifflin
$2.79 /

+0.055 (+2.01%)

HMHC Houghton Mifflin
$2.79 /

+0.055 (+2.01%)

10/05/20 Citi
Houghton Mifflin upgraded to Neutral from Sell at Citi
04/07/20 BMO Capital
Houghton Mifflin downgraded to Market Perform from Outperform at BMO Capital
04/03/20 Citi
Houghton Mifflin downgraded to Sell from Buy at Citi
03/10/20 Goldman Sachs
Houghton Mifflin upgraded to Neutral at Goldman Sachs after 43.5% pullback
HMHC Houghton Mifflin
$2.79 /

+0.055 (+2.01%)

Recommendations
Agilent price target raised to $115 from $100 at Citi » 06:30
11/24/20
11/24
06:30
11/24/20
06:30
A

Agilent

$112.18 /

+1.28 (+1.15%)

Citi analyst Patrick…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 8 minutes

Get Free Trial

ShowHide Related Items >><<
A Agilent
$112.18 /

+1.28 (+1.15%)

A Agilent
$112.18 /

+1.28 (+1.15%)

11/17/20 Cleveland Research
Agilent upgraded to Buy from Neutral at Cleveland Research
11/09/20 KeyBanc
Agilent initiated with an Overweight at KeyBanc
09/30/20 Atlantic Equities
Agilent initiated with a Neutral at Atlantic Equities
08/19/20 Needham
Agilent's Q3 results reflect COVID-19 recovery, says Needham
A Agilent
$112.18 /

+1.28 (+1.15%)

A Agilent
$112.18 /

+1.28 (+1.15%)

A Agilent
$112.18 /

+1.28 (+1.15%)

Upgrade
Schroders upgraded to Neutral from Underperform at BofA » 06:29
11/24/20
11/24
06:29
11/24/20
06:29
SHNWF

Schroders

$0.00 /

+ (+0.00%)

BofA analyst Hubert Lam…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SHNWF Schroders
$0.00 /

+ (+0.00%)

09/28/20 RBC Capital
Schroders initiated with an Underperform at RBC Capital
08/03/20 Berenberg
Schroders price target raised to 3,200 GBp from 2,203 GBp at Berenberg
07/15/20 UBS
Schroders price target raised to 3,175 GBp from 2,950 GBp at UBS
07/09/20 Morgan Stanley
Schroders price target lowered to 2,610 GBp from 2,640 GBp at Morgan Stanley
Recommendations
Nutanix price target raised to $30 from $26 at Piper Sandler » 06:28
11/24/20
11/24
06:28
11/24/20
06:28
NTNX

Nutanix

$28.42 /

-0.07 (-0.25%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NTNX Nutanix
$28.42 /

-0.07 (-0.25%)

NTNX Nutanix
$28.42 /

-0.07 (-0.25%)

05:18 Today Goldman Sachs
Nutanix upgraded to Neutral from Sell at Goldman Sachs
11/19/20 OTR Global
Nutanix upgraded to Positive from Mixed at OTR Global
11/18/20 Cleveland Research
Partners see previously stalled Nutanix projects return, says Cleveland Research
08/28/20
Fly Intel: Top five analyst downgrades
NTNX Nutanix
$28.42 /

-0.07 (-0.25%)

NTNX Nutanix
$28.42 /

-0.07 (-0.25%)

NTNX Nutanix
$28.42 /

-0.07 (-0.25%)

Recommendations
Align Technology price target raised to $525 from $500 at Piper Sandler » 06:26
11/24/20
11/24
06:26
11/24/20
06:26
ALGN

Align Technology

$476.56 /

+30.13 (+6.75%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ALGN Align Technology
$476.56 /

+30.13 (+6.75%)

ALGN Align Technology
$476.56 /

+30.13 (+6.75%)

11/23/20 Piper Sandler
Align Technology price target raised to $525 from $500 at Piper Sandler
11/10/20 William Blair
3D Systems upgraded to Market Perform from Underperform at William Blair
10/22/20 SVB Leerink
Align Technology price target raised to $460 from $340 at SVB Leerink
10/22/20 Jefferies
Align Technology price target raised to $450 from $355 at Jefferies
ALGN Align Technology
$476.56 /

+30.13 (+6.75%)

ALGN Align Technology
$476.56 /

+30.13 (+6.75%)

ALGN Align Technology
$476.56 /

+30.13 (+6.75%)

Downgrade
NatWest Group downgraded to Hold from Buy at HSBC » 06:25
11/24/20
11/24
06:25
11/24/20
06:25
RBSPF

NatWest Group

$0.00 /

+ (+0.00%)

HSBC analyst Robin Down…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
RBSPF NatWest Group
$0.00 /

+ (+0.00%)

05:31 Today HSBC
NatWest Group downgraded to Hold from Buy at HSBC
10/07/20 Investec
NatWest Group downgraded to Hold from Buy at Investec
10/07/20 Redburn
NatWest Group initiated with a Buy at Redburn
Downgrade
Lloyds Banking downgraded to Hold from Buy at HSBC » 06:24
11/24/20
11/24
06:24
11/24/20
06:24
LYG

Lloyds Banking

$1.94 /

+0.075 (+4.03%)

HSBC analyst Robin Down…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LYG Lloyds Banking
$1.94 /

+0.075 (+4.03%)

LYG Lloyds Banking
$1.94 /

+0.075 (+4.03%)

05:30 Today HSBC
Lloyds Banking downgraded to Hold from Buy at HSBC
11/02/20 UBS
Lloyds Banking price target raised to 38 GBp from 37 GBp at UBS
11/02/20 Berenberg
Lloyds Banking price target raised to 32 GBp from 30 GBp at Berenberg
09/18/20 Societe Generale
Lloyds Banking price target lowered to 40 GBp at Societe Generale
LYG Lloyds Banking
$1.94 /

+0.075 (+4.03%)

Initiation
uniQure assumed with a Buy at H.C. Wainwright » 06:23
11/24/20
11/24
06:23
11/24/20
06:23
QURE

uniQure

$46.50 /

+0.3 (+0.65%)

H.C. Wainwright analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
QURE uniQure
$46.50 /

+0.3 (+0.65%)

QURE uniQure
$46.50 /

+0.3 (+0.65%)

11/20/20 Baird
Baird ups uniQure target to $70, names 'Fresh Pick' into presentation
11/19/20 Cowen
uniQure data for EtranaDez 'very solid,' says Cowen
11/19/20 Chardan
uniQure's HOPE-B data supports Buy rating, says Chardan
11/11/20 Berenberg
Biotechnology companies initiated at Berenberg
QURE uniQure
$46.50 /

+0.3 (+0.65%)

QURE uniQure
$46.50 /

+0.3 (+0.65%)

QURE uniQure
$46.50 /

+0.3 (+0.65%)

Initiation
Allogene Therapeutics initiated with a Buy at BofA » 06:23
11/24/20
11/24
06:23
11/24/20
06:23
ALLO

Allogene Therapeutics

$30.59 /

-0.61 (-1.96%)

BofA analyst Jason…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$30.59 /

-0.61 (-1.96%)

ALLO Allogene Therapeutics
$30.59 /

-0.61 (-1.96%)

06:02 Today BofA
Allogene Therapeutics initiated with a Buy at BofA
11/04/20 Oppenheimer
Allogene weakness after abstract a buying opportunity, says Oppenheimer
11/04/20 Roth Capital
Question of safety with Allogene's Allo-CARs may be premature, says Roth Capital
11/04/20 Piper Sandler
Piper says Allogene should be bought on weakness after early abstract release
ALLO Allogene Therapeutics
$30.59 /

-0.61 (-1.96%)

  • 02
    Jun
Upgrade
Richemont upgraded to Neutral from Underperform at Credit Suisse » 06:22
11/24/20
11/24
06:22
11/24/20
06:22
RCHMY

Richemont

$0.00 /

+ (+0.00%)

Credit Suisse analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Recommendations
BeyondSpring price target lowered to $43 from $46 at H.C. Wainwright » 06:21
11/24/20
11/24
06:21
11/24/20
06:21
BYSI

BeyondSpring

$10.18 /

-0.185 (-1.78%)

H.C. Wainwright analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BYSI BeyondSpring
$10.18 /

-0.185 (-1.78%)

BYSI BeyondSpring
$10.18 /

-0.185 (-1.78%)

06/15/20 William Blair
BeyondSpring can 'disrupt' $6.5B neutropenia market, says William Blair
06/15/20 H.C. Wainwright
BeyondSpring price target raised to $46 from $30 at H.C. Wainwright
06/09/20 H.C. Wainwright
BeyondSpring data strengthen profile for Plinabulin, says H.C. Wainwright
02/07/20 Jefferies
Jefferies starts BeyondSpring at Buy, sees potential for new standard of care
BYSI BeyondSpring
$10.18 /

-0.185 (-1.78%)

  • 19
    Nov
  • 19
    Jun
BYSI BeyondSpring
$10.18 /

-0.185 (-1.78%)

Recommendations
NuCana price target lowered to $15 from $17 at H.C. Wainwright » 06:21
11/24/20
11/24
06:21
11/24/20
06:21
NCNA

NuCana

$4.66 /

-0.04 (-0.85%)

H.C. Wainwright analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NCNA NuCana
$4.66 /

-0.04 (-0.85%)

10/22/20 Truist
NuCana initiated with a Buy at Truist
10/22/20 Truist
NuCana initiated with a Buy at Truist
08/21/20 Piper Sandler
NuCana price target raised to $17 from $15 at Piper Sandler
07/24/20
Fly Intel: Top five analyst initiations
NCNA NuCana
$4.66 /

-0.04 (-0.85%)

  • 17
    Sep
NCNA NuCana
$4.66 /

-0.04 (-0.85%)

Initiation
Lufax initiated with a Sector Weight at KeyBanc » 06:20
11/24/20
11/24
06:20
11/24/20
06:20
LU

Lufax

$14.98 /

+0.355 (+2.43%)

KeyBanc analyst Hans…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LU Lufax
$14.98 /

+0.355 (+2.43%)

LU Lufax
$14.98 /

+0.355 (+2.43%)

05:20 Today BofA
Lufax initiated with a Buy at BofA
04:49 Today Goldman Sachs
Lufax initiated with a Buy at Goldman Sachs
  • 30
    Oct
Upgrade
Ferguson upgraded to Buy from Neutral at BofA » 06:18
11/24/20
11/24
06:18
11/24/20
06:18
FERGY

Ferguson

$0.00 /

+ (+0.00%)

BofA analyst Arnaud…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 8 minutes

Get Free Trial

ShowHide Related Items >><<
FERGY Ferguson
$0.00 /

+ (+0.00%)

11/19/20 JPMorgan
Ferguson price target raised to 8,700 GBp from 8,200 GBp at JPMorgan
11/10/20 Deutsche Bank
Ferguson price target raised to 10,100 GBp from 8,700 GBp at Deutsche Bank
10/01/20 Deutsche Bank
Ferguson price target raised to 8,700 GBp from 7,700 GBp at Deutsche Bank
10/01/20 Canaccord
Ferguson price target raised to 8,000 GBp from 7,460 GBp at Canaccord
Initiation
Atea Pharmaceuticals initiated with an Outperform at William Blair » 06:17
11/24/20
11/24
06:17
11/24/20
06:17
AVIR

Atea Pharmaceuticals

$33.39 /

+0.17 (+0.51%)

William Blair analyst Tim…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AVIR Atea Pharmaceuticals
$33.39 /

+0.17 (+0.51%)

  • 30
    Oct
Upgrade
Tenaris upgraded to Buy from Neutral at BofA » 06:16
11/24/20
11/24
06:16
11/24/20
06:16
TS

Tenaris

$15.41 /

+0.93 (+6.42%)

BofA analyst Frank McGann…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TS Tenaris
$15.41 /

+0.93 (+6.42%)

TS Tenaris
$15.41 /

+0.93 (+6.42%)

11/20/20 Stifel
Tenaris downgraded to Hold on limited upside post rally at Stifel
11/20/20 Stifel
Tenaris downgraded to Hold from Buy at Stifel
11/10/20 Barclays
Tenaris price target raised to EUR 5.30 from EUR 4.70 at Barclays
11/10/20 Morgan Stanley
Morgan Stanley downgrades Oil Field Services industry view to In-Line
TS Tenaris
$15.41 /

+0.93 (+6.42%)

Upgrade
IMI PLC upgraded to Overweight from Neutral at JPMorgan » 06:13
11/24/20
11/24
06:13
11/24/20
06:13
IMIAY

IMI PLC

$0.00 /

+ (+0.00%)

JPMorgan analyst Andrew…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IMIAY IMI PLC
$0.00 /

+ (+0.00%)

10/29/20 RBC Capital
IMI PLC price target raised to 1,260 GBp from 1,230 GBp at RBC Capital
10/28/20 Jefferies
IMI PLC price target raised to 1,285 GBp from 1,270 GBp at Jefferies
10/15/20 UBS
IMI PLC price target raised to 1,130 GBp from 1,070 GBp at UBS
10/02/20 Morgan Stanley
IMI PLC upgraded to Overweight from Equal Weight at Morgan Stanley
Periodicals
Intel quietly shuts down AR/VR project Intel Studios, Protocol reports » 06:12
11/24/20
11/24
06:12
11/24/20
06:12
INTC

Intel

$46.04 /

+0.64 (+1.41%)

Intel quietly shut down…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
INTC Intel
$46.04 /

+0.64 (+1.41%)

INTC Intel
$46.04 /

+0.64 (+1.41%)

11/23/20 Mizuho
Micron price target raised to $70 from $56 at Mizuho
11/13/20 Morgan Stanley
Few weeks delay of Ice Lake shouldn't be major Intel issue, says Morgan Stanley
11/13/20 Mizuho
Intel checks show Ice Lake delay not as bad as feared, says Mizuho
11/11/20 Credit Suisse
Credit Suisse likes move to Apple silicon on Mac, unified product portfolio
INTC Intel
$46.04 /

+0.64 (+1.41%)

INTC Intel
$46.04 /

+0.64 (+1.41%)

INTC Intel
$46.04 /

+0.64 (+1.41%)

INTC Intel
$46.04 /

+0.64 (+1.41%)

Downgrade
Paccar downgraded to Hold from Buy at Deutsche Bank » 06:11
11/24/20
11/24
06:11
11/24/20
06:11
PCAR

Paccar

$89.52 /

+0.67 (+0.75%)

Deutsche Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PCAR Paccar
$89.52 /

+0.67 (+0.75%)

PCAR Paccar
$89.52 /

+0.67 (+0.75%)

11/20/20 BofA
Paccar double-downgraded to Underperform, Allison cut to Neutral at BofA
11/20/20 BofA
Paccar downgraded to Underperform from Buy at BofA
10/22/20 Argus
Paccar upgraded to Buy from Hold at Argus
10/22/20 Argus
Paccar upgraded to Buy from Hold at Argus
PCAR Paccar
$89.52 /

+0.67 (+0.75%)

Upgrade
Yandex upgraded to Buy from Neutral at BofA » 06:10
11/24/20
11/24
06:10
11/24/20
06:10
YNDX

Yandex

$61.49 /

-0.52 (-0.84%)

BofA analyst Cesar Tiron…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
YNDX Yandex
$61.49 /

-0.52 (-0.84%)

YNDX Yandex
$61.49 /

-0.52 (-0.84%)

10/30/20 Jefferies
Yandex downgraded to Hold from Buy at Jefferies
10/29/20 Goldman Sachs
Yandex reinstated with a Buy at Goldman Sachs
09/23/20
Fly Intel: Top five analyst downgrades
09/23/20 BofA
Yandex downgraded to Neutral from Buy at BofA
YNDX Yandex
$61.49 /

-0.52 (-0.84%)

  • 25
    Jun
YNDX Yandex
$61.49 /

-0.52 (-0.84%)

Earnings
McCormick expects Cholula acquisition to be accretive to adj. EPS in 2021  06:09
11/24/20
11/24
06:09
11/24/20
06:09
MKC

McCormick

$182.89 /

-0.81 (-0.44%)

 
ShowHide Related Items >><<
MKC McCormick
$182.89 /

-0.81 (-0.44%)

MKC McCormick
$182.89 /

-0.81 (-0.44%)

09/24/20 Argus
McCormick initiated with a Buy at Argus
07/15/20 Credit Suisse
McCormick price target raised to $200 from $187 at Credit Suisse
06/26/20 Deutsche Bank
McCormick price target raised to $182 from $156 at Deutsche Bank
06/22/20 Jefferies
McCormick upgraded to Hold on sustainable food-at-home lift at Jefferies
MKC McCormick
$182.89 /

-0.81 (-0.44%)

MKC McCormick
$182.89 /

-0.81 (-0.44%)

MKC McCormick
$182.89 /

-0.81 (-0.44%)

Periodicals
McCormick nearing deal to buy hot sauce brand Cholula, WSJ reports » 06:09
11/24/20
11/24
06:09
11/24/20
06:09
MKC

McCormick

$182.89 /

-0.81 (-0.44%)

McCormick is in talks…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MKC McCormick
$182.89 /

-0.81 (-0.44%)

MKC McCormick
$182.89 /

-0.81 (-0.44%)

09/24/20 Argus
McCormick initiated with a Buy at Argus
07/15/20 Credit Suisse
McCormick price target raised to $200 from $187 at Credit Suisse
06/26/20 Deutsche Bank
McCormick price target raised to $182 from $156 at Deutsche Bank
06/22/20 Jefferies
McCormick upgraded to Hold on sustainable food-at-home lift at Jefferies
MKC McCormick
$182.89 /

-0.81 (-0.44%)

MKC McCormick
$182.89 /

-0.81 (-0.44%)

Upgrade
Sampo Oyj upgraded to Buy from Hold at Berenberg » 06:09
11/24/20
11/24
06:09
11/24/20
06:09
SAXPY

Sampo Oyj

$0.00 /

+ (+0.00%)

Berenberg analyst Michael…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SAXPY Sampo Oyj
$0.00 /

+ (+0.00%)

11/17/20 Deutsche Bank
Sampo Oyj downgraded to Hold from Buy at Deutsche Bank
11/17/20 Citi
Sampo Oyj downgraded to Neutral from Buy at Citi
11/11/20 Credit Suisse
Sampo Oyj price target lowered to EUR 31 from EUR 32.50 at Credit Suisse
11/06/20 Credit Suisse
Sampo Oyj price target raised to EUR 32.50 from EUR 28 at Credit Suisse

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.